A single arm phase II trial of chidamide plus cisplatin in advanced adenoid cystic carcinoma
Abstract
Systemic therapy for recurrent or metastatic adenoid cystic carcinoma remains limited, and durable disease control is difficult to achieve. We conducted a prospective, single-arm phase 2 trial of chidamide, a histone deacetylase inhibitor, plus cisplatin in 24 patients with recurrent or metastatic disease. Patients received a short chidamide lead-in followed by combination therapy for up to six cycles. The study did not meet its prespecified objective response target, with a confirmed objective response rate of 13.6% among 22 efficacy-evaluable patients. However, disease control was observed in 86.4% of patients, median progression-free survival was 17.9 months, and median overall survival was 40.3 months. Toxicity was manageable, with no treatment-related deaths. These findings support further evaluation of histone deacetylase inhibitor-platinum strategies as a disease-control approach in this rare cancer, while requiring validation in larger studies.
Related
- Initial Clinical Experience With Gemcitabine, Cisplatin, and Nivolumab for Advanced Urothelial Carcinoma: A Four-case Series
- FOLFOX plus nivolumab combination therapy for cisplatin-unfit patients with untreated advanced esophageal squamous cell carcinoma
- R0 resection following neoadjuvant PD-1 inhibition with paclitaxel-cisplatin is associated with improved overall survival in locally advanced and recurrent oral squamous cell carcinoma: multicenter retrospective cohort study.
- Proton beam therapy in the treatment of adenoid cystic carcinoma of the head and neck: a single enterprise retrospective cohort study
- Single-cell spatial transcriptomics identifies SERPINE1 as a vascular endothelial mediator of cisplatin resistance in head and neck squamous cell carcinoma.
BibTeX
@article{liu2026single,
title = {{A single arm phase II trial of chidamide plus cisplatin in advanced adenoid cystic carcinoma}},
author = {Yizhen Liu and Guang-Liang Chen and Kai Xue and Qunling Zhang and Zuguang Xia and Dongmei Ji and Jia Jin and Fangfang Lv and Xiaojian Liu and Yulong Wang and Xiaonan Hong and Junning Cao},
journal = {iScience},
year = {2026},
month = oct,
doi = {10.1016/j.isci.2026.117925},
url = {https://www.cell.com/iscience/fulltext/S2589-0042(26)03308-0},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - A single arm phase II trial of chidamide plus cisplatin in advanced adenoid cystic carcinoma
AU - Yizhen Liu
AU - Guang-Liang Chen
AU - Kai Xue
AU - Qunling Zhang
AU - Zuguang Xia
AU - Dongmei Ji
AU - Jia Jin
AU - Fangfang Lv
AU - Xiaojian Liu
AU - Yulong Wang
AU - Xiaonan Hong
AU - Junning Cao
PY - 2026
DA - 2026/10/23
JO - iScience
DO - 10.1016/j.isci.2026.117925
UR - https://www.cell.com/iscience/fulltext/S2589-0042(26)03308-0
AB - Systemic therapy for recurrent or metastatic adenoid cystic carcinoma remains limited, and durable disease control is difficult to achieve. We conducted a prospective, single-arm phase 2 trial of chidamide, a histone deacetylase inhibitor, plus cisplatin in 24 patients with recurrent or metastatic disease. Patients received a short chidamide lead-in followed by combination therapy for up to six cycles. The study did not meet its prespecified objective response target, with a confirmed objective response rate of 13.6% among 22 efficacy-evaluable patients. However, disease control was observed in 86.4% of patients, median progression-free survival was 17.9 months, and median overall survival was 40.3 months. Toxicity was manageable, with no treatment-related deaths. These findings support further evaluation of histone deacetylase inhibitor-platinum strategies as a disease-control approach in this rare cancer, while requiring validation in larger studies.
SN - 2589-0042
ER -